TuHURA Biosciences Approves Executive Salary Increases

TuHURA Biosciences ( (HURA) ) has shared an update.

On June 6, 2025, TuHURA Biosciences‘ Compensation Committee approved salary increases for CEO James A. Bianco and CFO Dan Dearborn, aligning their compensation with industry peers. Additionally, the company revised its Summary Compensation Table for fiscal year 2024, reflecting approved annual incentive bonuses and total compensation for key executives, indicating a strategic alignment with industry standards and enhancing transparency for stakeholders.

The most recent analyst rating on (HURA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.

Spark’s Take on HURA Stock

According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.

TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.

To see Spark’s full report on HURA stock, click here.

More about TuHURA Biosciences

TuHURA Biosciences, Inc. operates in the biotechnology industry, focusing on developing innovative therapeutic solutions. The company is involved in strategic partnerships and mergers to enhance its market positioning.

Average Trading Volume: 192,316

Technical Sentiment Signal: Sell

Current Market Cap: $118.8M

For a thorough assessment of HURA stock, go to TipRanks’ Stock Analysis page.